2nd Quarter - Report — MARSHALL & POPP, LLC for AMGEN USA INC. (2020)

Firm

MARSHALL & POPP, LLC

Client

AMGEN USA INC.

Income

$60,000

Expenses

—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Issues related to prescription drug value. Issues related to supply chain and Buy America requirements. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19/S.3129: Lower Costs, More Cures Act of 2019. Biosimilars. 340B issues. Patents and protection of intellectual property issues. Issues related to the COVID-19 pandemic, including patient access of Part B drugs. H.R.6800: The Heroes Act.

Lobbyist	Covered position, as disclosed
HAZEN CLAY MARSHALL	Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles
MONICA POPP	Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint

Contacted: White House Office; HOUSE OF REPRESENTATIVES; Office of Management & Budget (OMB); Health & Human Services, Dept of (HHS); Centers For Medicare and Medicaid Services (CMS); Natl Economic Council (NEC); SENATE

Bills named: H.R. 19 (116th), H.R. 3 (116th), S. 3129 (116th), H.R. 6800 (116th), S. 2543 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.